AMGN Stock Recent News

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amgen Inc.'s diversified portfolio ensures steady revenue but modest growth, with no single drug contributing more than 15% to total revenue. Recent revenue growth and margin upticks are promising, but sustainability remains uncertain amid biosimilar competition and pricing pressures. High debt levels and slow deleveraging, particularly from the Horizon Therapeutics acquisition, pose risks to future M&A and capital efficiency.

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.

Amgen reported strong Q1 results with a 9% YoY revenue increase and a 24% rise in operating EPS, but shares dipped due to risk-on market sentiment. Despite competitive pressures and softer EPS trends, Amgen remains undervalued with a high dividend yield of 3.39% and robust free cash flow. Key risks include emerging therapies and macroeconomic factors, but positive Phase III data and new product launches support a buy-the-dip strategy.

Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding the single share price, supported by adequate free cash flow. Analyst projections suggest top Dow Dogs could net gains between 21.02% and 45.17% by May 2026, with an average net gain of 32.18%. 28 of 30 current Dow-listed stocks pay dividends. As of 5/1/25, the top ten ranged from 2.64%-6.26% by annual yield, and another top ten ranged from 18.06%-46.15% in broker-estimated target-price-upsides.

Watch as the Investment Committee breaks down the latest market movers and shakers.

LOS ANGELES, May 2, 2025 /PRNewswire/ -- Landmark Science, a premier provider of real-world evidence (RWE) solutions, is redefining industry standards with its white-glove, high-touch approach to evidence generation. With long-standing roots in biopharma, Landmark Science bridges the gap between vendors and biopharma, delivering agile and efficient solutions uniquely tailored to clients. This hand-held approach through and through helps clients avoid typical red tape situations that can delay or halt critical evidence generation to swiftly transform evidence into insights on patient care, access, and outcomes. Landmark Science founder and CEO, Shivani Aggarwal, PhD, MS, brings 15 years of experience in RWE and clinical trials from her time at leading life science companies Amgen, Regeneron, and IQVIA. With deep scientific acumen and a strong track record in evidence generation, Shivani Aggarwal drives Landmark Science's strategic vision, spearheading the delivery of innovative, data-dr

AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products, Prolia, Xgeva, Repatha, Blincyto and Evenity beat estimates.